Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 6, 2009, Pages

  Ogbogu, Princess U ^a   Bochner, Bruce S ^b   Butterfield, Joseph H ^c   Gleich, Gerald J ^d   Huss Marp, Johannes ^e,f   Kahn, Jean Emmanuel ^g,h   Leiferman, Kristin M ^d   Nutman, Thomas B ^a   Pfab, Florian ^e,f   Ring, Johannes ^f   Rothenberg, Marc E ⁱ   Roufosse, Florence ^j,k   Sajous, Marie Helene ^b   Sheikh, Javed ^l   Simon, Dagmar ^m   Simon, Hans Uwe ⁿ   Stein, Miguel L ⁱ   Wardlaw, Andrew ^o   Weller, Peter F ^l   Klion, Amy D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g FOCH HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j ERASME HOSPITAL   (Belgium)

^k UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^l HARVARD MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF BERN   (Switzerland)

ⁿ UNIVERSITY OF BERN   (Switzerland)

^o UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CEPTION; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN; MEPOLIZUMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISONE; RESLIZUMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; DEMOGRAPHY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EOSINOPHILIA; FEMALE; FIP1L1 GENE; GENE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PDGFRA GENE; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

EID: 71249101922     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.022     Document Type: Article

References (17)

1. Chusid M.J., Dale D.C., West B.C., and Wolff S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54 (1975) 1-27
2. Weller P.F., and Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 83 (1994) 2759-2779
3. Simon H.U., Plotz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
4. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
5. Klion A.D., Noel P., Akin C., Law M.A., Gilliland D.G., Cools J., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib-responsiveness. Blood 101 (2003) 4660-4666
6. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H.U., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
7. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228
8. Roufosse F., Cogan E., and Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 27 (2007) 389-413
9. Simon H.U., and Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 27 (2007) 519-527
10. Bush R.K., Geller M., Busse W.W., Flaherty D.K., and Dickie H.A. Response to corticosteroids in the hypereosinophilic syndrome: association with increased serum IgE levels. Arch Intern Med 138 (1978) 1244-1246
11. de Lavareille A., Roufosse F., Schmid-Grendelmeier P., Roumier A.S., Schandene L., Cogan E., et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 110 (2002) 476-479
12. Simon D., Salemi S., Yousefi S., and Simon H.U. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 121 (2008) 1054-1056
13. Stein M.L., Villanueva J.M., Buckmeier B.K., Yamada Y., Filipovich A.H., Assa'ad A.H., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121 (2008) 1473-1483
14. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., et al. FIP1L1/PDGFRA fusion: prevalence and clinicopathologic correlates in 89 patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
15. Vaklavas C., Tefferi A., Butterfield J., Ketterling R.P., Vertovsek S., Kantarjian H., et al. Idiopathic" eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 31 (2007) 691-694
16. Roche-Lestienne C., Lepers S., Soenen-Cornu V., Kahn J.E., Lai J.L., Hachulla E., et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19 (2005) 792-798
17. Klion A.D., Law M.A., Noel P., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome. Blood 103 (2004) 2939-2941